Skip to main content

Blog

REGENXBIO announces interim clinical data from Phase I/II AFFINITY DUCHENNE™ trial of RGX-202

...

WATCH: Advocating for Access: Insurance 101 (Webinar Recording)

...

Edgewise Therapeutics Now Enrolling GRAND CANYON Study of EDG-5506 in Individuals with Becker Muscular Dystrophy

...

Miles for Matthew Celebrates 15 Years

...

CDCC Spotlight: Children’s Hospital Los Angeles

...

Entrada Therapeutics starts dosing in ENTR-601-44 Phase 1 trial

...

RSV, COVID, and Flu – oh my!

...

PTC Therapeutics Announces Negative European Medicines Agency Opinion Regarding Full Authorization of Translarna

...

Game Day Tips for Coach to Cure MD 2023

...

Duchenne Action Month: Ways to get involved with PPMD

...